Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Extension Treatment Protocol for Subjects Who Have Participated in a Phase 3 Study of Tivozanib vs. Sorafenib in Renal Cell Carcinoma (Protocol AV-951-09-301)

Trial Profile

An Extension Treatment Protocol for Subjects Who Have Participated in a Phase 3 Study of Tivozanib vs. Sorafenib in Renal Cell Carcinoma (Protocol AV-951-09-301)

Completed
Phase of Trial: Phase III

Latest Information Update: 21 Mar 2018

At a glance

  • Drugs Tivozanib (Primary) ; Sorafenib
  • Indications Renal cell carcinoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Astellas Pharma; AVEO Oncology
  • Most Recent Events

    • 21 Mar 2018 Results (n=161) published in an AVEO Oncology Media Release
    • 13 Mar 2018 Results (n=161) assessing efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma published in the European Journal of Cancer
    • 22 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top